This Review provides a practical phenotype-directed treatment algorithm incorporating atherosclerotic cardiovascular disease, obesity, type 2 diabetes, chronic kidney disease, HFpEF, sodium–glucose cotransporter 2 inhibitor use and patient-specific treatment constraints.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide have expanded from glucose-lowering therapy into cardiovascular medicine. In type 2 diabetes, several long-acting GLP-1RAs reduce major adverse cardiovascular events (MACE). SELECT extended this benefit to adults with established cardiovascular disease and overweight or obesity without diabetes, while SOUL demonstrated MACE reduction with oral semaglutide. SURPASS-CVOT established cardiovascular noninferiority of tirzepatide to dulaglutide but did not demonstrate superiority. Obesity-related heart failure with preserved ejection fraction (HFpEF) has emerged as a particularly responsive phenotype: semaglutide improves symptoms and physical function, whereas tirzepatide also reduces worsening heart failure events. FLOW further supports kidney and cardiovascular protection with semaglutide in type 2 diabetes and chronic kidney disease. Randomised human studies support effects on adiposity, haemodynamic burden, inflammation and cardiorenal outcomes, whereas endothelial, coronary microvascular and direct myocardial mechanisms remain less clinically validated. This Review integrates the current evidence, distinguishes randomised outcomes from observational and mechanistic signals, and provides a practical phenotype-directed treatment algorithm incorporating atherosclerotic cardiovascular disease, obesity, type 2 diabetes, chronic kidney disease, HFpEF, sodium–glucose cotransporter 2 inhibitor use and patient-specific treatment constraints. Current practice should be guided by indication-specific outcome evidence rather than weight-loss magnitude or indirect cross-trial comparisons.
Cardiovascular-kidney-metabolic (CKM) syndrome reflects the complex interplay among cardiovascular disease, chronic kidney disease, type 2 diabetes, and obesity. GLP-1 receptor agonists and tirzepatide have emerged as important therapeutic options within CKM syndrome, although the strength and maturity of evidence diff...
Filip Kierzkowski, Wiktoria Skrzypek, W. Bryl et al.· Frontiers in Endocrinology· 0 citations
The impact of type 2 diabetes (T2D) extends beyond mere management of blood glucose; it also encompasses related cardiovascular, renal and metabolic issues. This interconnected framework, known as the cardio-renal-metabolic (CRM) syndrome, calls for a shift in therapeutic approach. While traditional treatments have mad...
Clipper F. Young, Namrita George, Alexander Olson et al.· touchREVIEWS in Endocrinolog...· 0 citations
INTRODUCTION
Heart failure with preserved ejection fraction (HFpEF) accounts for over half of all heart failure hospitalisations and is increasing in prevalence, largely driven by obesity and Type 2 Diabetes Mellitus (T2DM). Glucagon-like-peptide receptor agonists (GLP-1 RAs) and the dual GLP-1/GIP agonist, tirzepatide...
R. Chotalia, Owais Ghias, Muhammad Usman Shah et al.· Expert Review of Cardiovascu...· 0 citations
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have evolved from glucose-lowering agents for type 2 diabetes (T2D) into multifunctional therapies with effects extending across multiple metabolic and organ systems. This review summarizes current evidence regarding the pleiotropic effects, safety profile, and futur...
M. Bukowska, Katarzyna Otrębska, Dominika Lewandowska et al.· International Journal of Inn...· 0 citations
Obesity is a rapidly increasing global health challenge that is strongly linked to the cardiorenometabolic syndrome, cardiovascular morbidity, and mortality. Lifestyle interventions remain the cornerstone of treatment, but average long-term weight loss is modest and durable weight maintenance is often limited. Bariatri...
Susan J. F. van Maren, Eveline P. M. van Doorn, Mark M. Smits et al.· Netherlands Heart Journal· 1 citation
Obesity is now a major global public health concern and a recognised risk factor for Cardiovascular
Disease (CVD), the leading cause of morbidity and mortality worldwide. Chronic lowgrade
inflammation, oxidative stress, insulin resistance, dyslipidemia, and endothelial dysfunction
are promoted by excessive adiposit...
Amandeep Kaur, Okesh Saini, M. Haneef et al.· Glucolipid Metabolic Disorde...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.